1 / 49

Universal Screening for Lynch Syndrome

Universal Screening for Lynch Syndrome. Cecelia Bellcross, PhD, MS, CGC Emory University School of Medicine Department of Human Genetics. Genetics of CRC. Sporadic (65 %– 85%). Familial (10 %– 30%). Rare CRC syndromes (<0.1%).

aleta
Télécharger la présentation

Universal Screening for Lynch Syndrome

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Universal Screening for Lynch Syndrome Cecelia Bellcross, PhD, MS, CGC Emory University School of Medicine Department of Human Genetics

  2. Genetics of CRC Sporadic (65%–85%) Familial (10%–30%) Rare CRC syndromes (<0.1%) Lynch syndrome (aka Hereditary nonpolyposis colorectal cancer -HNPCC) (3%) MYH associated polyposis (MAP) (1%) Familial adenomatous polyposis (FAP) (1%)

  3. Early but variable age at CRC diagnosis (~45 years) Tumor site in proximal colon predominates Metachronous/synchronous CRCs Extracolonic cancers:endometrium, ovary, stomach, urinary tract, small bowel, bile duct, pancreatic, sebaceous skin tumors; brain tumors Clinical Features of Lynch/HNPCC

  4. A Classic HNPCC/Lynch Family CRC dx 50s CRC dx 45 CRC dx 61 CRC dx 75 OvarianCa, dx 64 CRC dx 48 CRC dx 52 EndometrialCa, dx 59 45 CRC dx 42

  5. Other Features of Lynch Syndrome • Autosomal dominant inheritance • Genes belong to DNA mismatch repair (MMR) family • Genetic heterogeneity (MLH1, MSH2, MSH6, PMS2) • CRC lifetime risk 30-80% • Endometrial cancer lifetime risk 30-60%

  6. CRC RISK *Barrow, Clin Genet 2008

  7. Extra-colonic/Extra Endometrial Lifetime Cumulative Incidence to age 70 yo: • Urologic tract (8.4% overall) • MLH1: female =1.1%, Male = 3.7% • MSH2: female =11.9%, Male = 27.8% • Ovary = 6.7% • Gastric = 5.8% • Small Bowel = 4.3% • Biliary/Pancreatic = 4.1% Watson, Int. J. Cancer, 2008

  8. Surveillance/Prevention Options for Lynch syndrome (Lindor JAMA, 2006;296:1507)

  9. Impact of Screening Percent Jarvinen, Gastroent, 2000 Jarvinen, JCO, 2009: 242 mutation +, 367 mutation - : >95% screening compliance, no difference in cancer or all cause mortality rates

  10. Amsterdam II Criteria • 3 or more relatives with verified HNPCC associated tumor (CRC, endometrial, ovarian, gastric, small bowel, urinary tract) in family • One case a first-degree relative of the other two • Two or more generations involved • One or more cancer diagnosed by age 50 • FAP excluded Failure to meet these criteria does not exclude HNPCC

  11. Revised Bethesda Guidelines: • CRC < age 50 • Patient with 2 HNPCC related tumors • Patient with CRC < age 60 with MSI-H histology • Patient with CRC with 1st degree relative with HNPCC related cancer; one of the cancers at < 50 years • Patient with CRC and 2 or more relatives with HNPCC-related cancer regardless of age Umar, JNCI, 2004

  12. Microsatellite Instability Normal Cells -CG- -CGCGCGCG -CG- -CGCGCGCG -CG -CGCGCGCG- -CG- -CGCGCGCG Normal Microsatellites Tumor Cells -CG- -CG- -CG- -CGCG- -CGCGCG- -CGCGCGCGCG- -CGCGCGCGCG- -CGCGCG- -CG- -CGCG- Microsatellite Instability

  13. Immunohistochemistry Abnormal or missing MSH2 protein Abnormal Gene (MSH2) Lack of MSH2 expression, negative IHC staining for MSH2 protein MSH2+ MSH2- Normal tissue Tumor tissue

  14. Testing for Lynch/HNPCC Family/Medical history meets screening criteria Amsterdam/Bethesda MSI/IHC on tumor tissue MSI-High IHC – loss of protein expression MSI normal IHC normal No further testing Risks & screening based on history Genetic Testing on blood No mutation Identified 1. Consider additional genetic testing 2. Risks & screening based on test results and family/medical history Mutation Identified Lynch/HNPCC screening & management Family members offered testing

  15. Rationale for HNPCC/Lynch Syndrome Screening of Newly Diagnosed CRC • Common: ~ 3% of all CRC • Age/screening criteria miss up to 25% • Accurate methods (MSI/IHC) using easily accessible tumor tissue • Benefits of medical intervention • Cascade testing of family members • Surveillance/prevention • CRC treatment decisions • Evidence of cost-effectiveness

  16. EGAPP Lynch RecommendationGenetics in Medicine January 2009 GIM, 2009;1:35 May, 2007 www.ahrq.gov/downloads/pub/evidence/pdf/hnpcc/hnpcc.pdf GIM, 2009;1:42

  17. Summary Statement “The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group found sufficient evidence to recommend offering genetic testing for Lynch syndrome to individuals with newly diagnosed colorectal cancer (CRC) to reduce morbidity and mortality in relatives. We found insufficient evidence to recommend a specific genetic testing strategy among the several examined.”

  18. 2.8% of CRC probands with deleterious mutations (n=44) Age at diagnosis – 51.4 (range 23-87) 50% diagnosed over age 50 25% did not meet either Amsterdam or Bethesda criteria Mutations 20.5% MLH1 52.3% MSH2 13.6% MSH6 13.6% PMS2 Columbus-area HNPCC study (1999-2005) Hampel et al. New Engl J Med 2005; 352:1851 Hampel et al. J ClinOncol 2008; 26:5783

  19. Family Studies of 35/44 CRC Probands 35 CRC probands have had genetic counseling Degree of Kinship Tested Positive First 99 52 Second 64 28 > Second 86 29 Total 249 109 Hampel et al. NEJM 2005;352:1851-60.; Hampel et al. JCO 2008.

  20. Theoretical Population Health Benefit Bellcross, Genet Med, 2012

  21. Healthy People 2020 Approved Genomics Objective (Developmental) “Increase the proportion of persons with newly diagnosed colorectal cancer who receive genetic testing to identify Lynch syndrome”

  22. Endometrial cancer 2.5 % with deleterious mutations (n=14) • Age at diagnosis – 54.1 (range 39-69) • 65% diagnosed over age 50 • 65% did not meet either Amsterdam or Bethesda criteria • Mutations • 14.3% MLH1 • 21.4% MSH2 • 64.3% MSH6 • No PMS2 Hampel H et al. Cancer Res. 2006; 66:7810 Hampel H et al. Cancer Res. 2007;67:9603

  23. Columbus HNPCC study Family studies of 14 EC probands 12/14 EC probands have had genetic counseling Degree of Kinship Tested Positive First 28 16 Second 12 3 > Second 8 2 Total 48 21

  24. EGAPP Data Interpretation Concerns • “To reduce morbidity and mortality in relatives” • Implies no benefit to proband • Increasing evidence of impact on CRC management – chemotherapy, surgery • Known increased risk for 2nd primary colorectal cancers and other tumors impacts medical management • Does not take into account current practice and insurance coverage (including Medicare)

  25. Potential Impact on CRC treatment • MSI-H tumors • Better prognosis (Popat, JCO 2005;23:609) • Lack of impact of 5FU on RFS/OS (DesGuetz, Eur J Cancer 2009;45:1890) • Surgical (Gut 2011;60:950 – 382 LS gene mutation carriers • Extensive colectomy – 0/50 metachronous tumors vs. Segmental resection – 74/322 (22%) • Cumulative risk of metachronous CRC at 10, 20, & 30 yrs = 16%, 41% & 62% respectively

  26. Cost effectiveness Data Targeting screening only to CRCs < age 50 would miss over 50% of LS cases Mvundura M, et al. Genet Med. 2010;12:93-104

  27. Business Analysis by a Healthcare System • Evidence review & computerized simulation models – Intermountain Healthcare • Cost of screening all (unselected) CRC patients for Lynch syndrome <$25,000/LYS • IHC with methylation studies, reflexing to BRAF most efficient Gudgeon, Am J Managed Care, 2011;17:e288

  28. Universal IHC screening for CRC: OSU experience Began March 1, 2006 270 cases of CRC in first 2 years 57 (21.1%) absent for one or two MMR proteins 54 contacted by genetics with physician consent 5 deceased, reported to next of kin 7 prisoners 34 appropriate for consultation 18 scheduled appointment/9 completed appt 7/9 tested 2 confirmed Lynch, 3 with MLH1 methylation South et al, Genet Med 2009; 11:812-817

  29. Challenges to Implementation • Lack of provider knowledge of Lynch syndrome and testing issues • Question of informed consent • Availability of genetic services • Cost and coverage • Psychosocial impact • Informing relatives – who is responsible? • Patient and provider compliance • Infrastructure needs • Testing limitations (e.g. IHC accuracy by site)

  30. It takes a team Surgery Pathology Oncology Gastroenterology Genetics Gynecology Patients Families Healthcare system

  31. http://www.lynchscreening.net

  32. LSSN Vision and Mission • LSSN Vision: • to reduce the cancer burden associated with Lynch syndrome. • LSSN Mission: • to promote universal Lynch syndrome screening on all newly diagnosed colorectal and endometrial cancers; to facilitate the ability of institutions to implement appropriate screening by sharing resources, protocols and data through network collaboration; and to investigate universal screening for other Lynch syndrome related malignancies

  33. Membership Data

  34. Emory LS Screening Team N. VolkanAdsay, MD Pathology Cecelia A. Bellcross PhD, MS, CGC Genetics Amanda Eppolito, MS, CGC Genetics Alton B. Farris, III, MD Pathology Natalyn N. Hawk, MD Hem/Onc Ira R. Horowitz, MD Gyn/Onc John Kauh, MD Hem/Onc NamitaKhanna, MD Gyn/Onc Dana M. Meaney-Delman, MD High Risk Gyn Virginia O. Shaffer, MD Colorectal Surgery Christine Stanislaw, MS, CGC Genetics Patrick S. Sullivan, MD Colorectal Surgery Miranda Chergosky – GC Student Focus Intern

  35. Emory LS Screening Protocol

  36. IHC Result Interpretation

  37. Genetics Follow-up • Access to CoPath – automatic search for all CRC specimens • Monitor if IHC being done – interface with GI path fellows • Review IHC/BRAF results • Enter into LSSN database • Abnormal IHC results • Follow-up letter to MD via EMR • Coordination with RN staff to ensure genetics referral • Subset of IHC positive screens to be seen at point of care (post-op or oncology appt) • Enter follow-up/outcome data into LSSN db

  38. WhatIs Cancer Genetic Counseling? • Cancer genetic counseling is NOT genetic testing! • It is a process of information gathering, risk assessment and education. • The goal of cancer genetic counseling is to provide the individual, family and their health care providers with accurate cancer risk information to facilitate personal management decisions.

  39. Initial Genetic Counseling Visit • Review medical history and family history • Assess risk for hereditary cancer • Discuss cancer biology and genetics • Discuss genetic testing options and/or referrals for additional evaluation if appropriate • Discuss implications of testing for the patient and their family • Coordinate testing including review of insurance issues

  40. Informed Consent:Potential Benefits of Genetic Testing • Improved cancer risk management • Prevention • Early detection • Avoidance of unnecessary and costly screening and surgery • Relief from uncertainty and anxiety about cancer risk • Information for individual and family members • Lifestyle decision making

  41. Informed Consent:Limitations of Genetic Testing • Not all mutations are detectable • Uncertain significance of some mutations • Negative result is fully informative only if mutation has been identified in family • Results indicate probability, not certainty, of developing cancer • Management/screening strategies continually evolving as new data collected

  42. Ideally, Begin Testing With an Affected Person Colon Ca, 42 Test first, if possible Colon Ca, 45 Colon Ca, 38 d.45 Person seeking counseling (proband) If a mutation is found in an affected person, testing will be more informative for other family members.

  43. Understanding Possible Test Results Increased Cancer Risk Positive NO Increased Cancer Risk Y Has a mutation been found in the family? Negative N Cancer Risk Not Altered (individualized empiric risk based on family history) Uncertain Variant

  44. Impact of Genetic Testing Family with known mutation Colon Ca, 52 d. 50 MSH2? Colon Ca, 45 MSH2 + Endometrial Ca, 47 * 30 MSH2+ 37 MSH2- Mutation Positive: initiate screening True negative:no increased risk beyond general population

  45. Informed Consent:Potential Risks of Genetic Testing • False sense of security if test negative • Psychological distress • Change in family dynamics • ?? Insurance discrimination

  46. The Myth of Genetic Discrimination • No well-documented cases of health insurance loss, denial, or rate • increase based on cancer genetic • testing • State and Federal laws exist • which address health insurance and employment • GINA – Genetic Information Non-discrimination Act (May, 2008) • Life/disability/long-term care not protected

  47. Result Disclosure and Post-test Counseling • Assess cancer risk based on test results • Discuss any additional testing recommendations • Review of implications for family members • Present screening and management options • Discuss risk reduction strategies • Explore psychosocial adjustment to cancer risk and/or genetic risk

  48. QuestionsCommentsThoughtsSuggestions? Thank You

More Related